Yubo International Biotech Limited
YBGJ
$0.053
$0.00367.29%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -97.77% | -66.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -97.77% | -66.47% |
| Cost of Revenue | -202.38% | 4.62% | 25,480.00% | -99.19% | -88.83% |
| Gross Profit | -76.24% | -125.66% | -14,311.11% | -95.32% | -37.37% |
| SG&A Expenses | -21.57% | 43.46% | 42.55% | 1.67% | 276.71% |
| Depreciation & Amortization | -63.16% | 5.31% | 144.81% | 384.38% | 909.65% |
| Other Operating Expenses | -47.14% | 494.56% | -6.73% | -6.26% | -51.63% |
| Total Operating Expenses | -34.58% | 47.15% | 62.27% | -13.09% | 1,558.38% |
| Operating Income | 31.76% | -9,804.69% | -62.89% | -28.54% | -599.81% |
| Income Before Tax | 31.79% | -9,958.73% | -62.89% | -29.30% | -599.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.79% | -9,958.73% | -62.89% | -29.30% | -599.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.01% | -9,319.05% | -43.62% | -19.13% | -599.42% |
| EBIT | 31.76% | -9,804.69% | -62.89% | -28.54% | -599.81% |
| EBITDA | 22.79% | -1,170.47% | -58.25% | -17.44% | -450.13% |
| EPS Basic | 44.19% | -4,900.00% | -41.94% | -19.23% | -577.78% |
| Normalized Basic EPS | 51.85% | -- | -31.58% | -11.76% | -640.00% |
| EPS Diluted | 44.19% | -4,900.00% | -41.94% | -19.23% | -577.78% |
| Normalized Diluted EPS | 51.85% | -- | -31.58% | -11.76% | -640.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
